BioSpace News Archive

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer.

Bristol Myers Squibb and RayzeBio, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.

Brainstorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes.

electroCore, Inc. announced that it has received patent issue notifications from the United States Patent and Trademark Office.

Bionano Genomics, Inc. announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping to a combined workflow of chromosomal microarray analysis and karyotyping.

Zymeworks Inc. announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC, for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par value per share, in a private placement.

Oncternal Therapeutics, Inc. updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.

Amgen announced that the U.S. Food and Drug Administration has completed its review of the company’s supplemental New Drug Application seeking full approval of LUMAKRAS®.

Nectin Therapeutics Ltd. announced that it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy arm with the immune-oncology drug KEYTRUDA®, MSD’s anti-PD-1 therapy, and expanded the trial to four additional global sites to include Sheba Medical Center, Hadassah Medical Center, Ochsner Health, and City of Hope along with flagship site, MD Anderson Cancer Center.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces positive results from a pivotal clinical study for its proprietary Valacyclovir Oral Suspension.